GlassScriptPhysician profile
Taryn Lamorte
NPI 1417595844
$2,557.43
in general payments reported to CMS, 2019-2025
13 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $529 · 2023: $1,282 · 2024: $286 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $841.36 | 2021-2024 | Xarelto |
| Atricure, INC. | $508.23 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $488.95 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $414.94 | 2021-2024 | Repatha |
| Genzyme Corporation | $113.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.70 | 2023-2025 | |
| Novo Nordisk INC | $29.37 | 2025 | Rivfloza |
| Kestra Medical Technology Services, INC. | $26.90 | 2023 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $19.43 | 2025 | Evkeeza |
| Pfizer INC. | $18.81 | 2024 | |
| Lilly USA, LLC | $15.43 | 2024 | Zepbound |
| Boston Scientific Corporation | $13.98 | 2024 | Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Lamorte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.